Big Move For Vaccinex, Inc.

Vaccinex, Inc. (VCNX:NASDAQ) soared at $1.51, a gain of 33.6%. On Fri, Jan 28, 2022, VCNX:NASDAQ touched a New 2-Week High of $1.13. The stock got featured on our News Catalysts scanner on Fri, Jan 28, 2022 at 11:17 AM in the 'BIOTECH' category. From Tue, Jan 18, 2022, the stock recorded 37.50% Up Days and 22.22% Green Days

The stock spiked on Wed, Jan 26, 2022 at $1.28 with a volume of 42M+.

About Vaccinex, Inc. (VCNX:NASDAQ)

Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its lead product candidate VX15 is in clinical development for the treatment of NSCLC, osteosarcoma and Huntington's disease and additional product candidates VX5 and VX25 are in earlier stages of development.